Clen · Clenbuterol HCl
Clenbuterol is a long-acting beta-2 adrenergic receptor agonist originally developed as a bronchodilator for the treatment of reversible airway obstruction (asthma, chronic obstructive pulmonary disease). It has been approved for human respiratory use in several countries (for example certain European, Latin American, and Asian markets) under brand names such as Spiropent, Ventipulmin, and Broncodil. In the United States it is not FDA-approved for human use; it is used in veterinary medicine as a bronchodilator in horses and is prohibited in food-producing animals.
Take in the morning given the ~36 hour half-life - evening dosing disrupts sleep for most users. Start at 20 mcg/day and increase gradually every 2-3 days, monitoring resting heart rate, blood pressure, and tremor. Classic cycling is 2 weeks on / 2 weeks off to limit beta-2 desensitization. Supplement potassium and taurine to offset hypokalemia and muscle cramps.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
Clenbuterol is a selective beta-2 adrenergic receptor agonist. Stimulation of beta-2 receptors on bronchial smooth muscle produces relaxation and bronchodilation, which is the basis for its approved respiratory use. The same receptor agonism in adipose tissue activates hormone-sensitive lipase via the cAMP / PKA pathway, driving lipolysis, and stimulation of beta-2 receptors in skeletal muscle produces a modest anti-catabolic and anabolic-sparing effect in animal models.
Thermogenesis is driven by increased metabolic rate, elevated body temperature, and increased oxygen consumption - typical effects of sympathetic activation. Because of clenbuterol's very long half-life (approximately 36 hours) and tissue accumulation, effects persist well beyond each dose, and beta-2 receptor desensitization develops within 2-3 weeks of continuous use, which is why intermittent dosing schedules (2 weeks on / 2 weeks off, or similar) are common.
At higher doses, cardiac beta-1 and beta-2 agonism causes tachycardia, increased contractility, and can produce cardiac hypertrophy and arrhythmia risk with prolonged use. Electrolyte disturbances (notably hypokalemia) are characteristic of beta-2 agonist overuse.
First 1-3 days: elevated resting heart rate, hand tremor, sweating, and sleep disturbance. Thermogenic sensation (warmth) is typically noticeable within 30-60 minutes of the first dose.
Week 1-2: measurable fat loss under an appropriate caloric deficit, often with preserved strength output. Tremor usually subsides as tolerance builds. Muscle cramps are common without potassium/taurine supplementation.
Week 2 onward: receptor desensitization begins to blunt the thermogenic effect. The 2-weeks-off phase restores sensitivity. Extending continuous use beyond 3-4 weeks without a break compounds cardiac risk for diminishing returns.
Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.
Oral ingestion was the most common route in a systematic review of athlete clenbuterol adverse-event cases.
Oral ingestion of clenbuterol was the most preferred route among them.
Adverse events of clenbuterol among athletes: a systematic review of case reports and case series.
Evidence scope. Athlete case reports/series, not a therapeutic trial or evidence that oral use is safe or effective for fat loss.
Athlete adverse-event reports included daily clenbuterol doses beginning at 20 micrograms.
The daily administered dose of clenbuterol was ranging from 20 µg to 30 mg.
Adverse events of clenbuterol among athletes: a systematic review of case reports and case series.
Evidence scope. The 20-microgram figure is the lower bound of a toxicity-case range extending to 30 mg; it is not a recommended starting dose.
Clenbuterol is an oral, brain-penetrant beta-2 adrenergic receptor agonist.
This study investigated the safety and effects on regional cerebral blood flow (rCBF) of the oral, brain-penetrant β2-AR agonist, clenbuterol, in healthy volunteers (HV) and patients with mild cognitive impairment (MCI) or Parkinson's disease (PD).
Evidence scope. Human single-dose study; supports receptor class and oral activity, not the page’s detailed adipose mechanism or bodybuilding indication.
Cardiac complications were the most common adverse events in athlete case reports.
The cardiac-related complications were the most commonly occurring adverse events.
Adverse events of clenbuterol among athletes: a systematic review of case reports and case series.
Evidence scope. Twenty-three case reports/series involving 24 athletes; cannot estimate incidence at 20 micrograms/day.
A 5,000-microgram intentional ingestion produced profound hypokalemia and biochemical myocardial injury.
Bloodwork revealed a potassium of 2.0 mmol/L, peak lactate of 9.4 mmol/L, and peak troponin of 5.39 μg/L.
Case report and review of clenbuterol cardiac toxicity.
Evidence scope. Single overdose case at 125 times the cited adult dose; establishes hazard, not risk at the page’s start dose.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Exact quick-start regimen: 20 mcg orally once daily for fat loss. The amount appears only as the lower bound of athlete adverse-event reports; no checked controlled abstract validates it as a fat-loss starting regimen.
Detailed mechanism: adipose cAMP/PKA lipolysis, thermogenesis, and 2-3 week receptor desensitization. The selected human abstract establishes beta-2 agonism but not this full mechanism and time course.
Unusually long for a beta-2 agonist
Oral
Oral
Per dose - supports once daily dosing
Hepatic metabolism with renal excretion of unchanged drug and metabolites.
Storage. Store at controlled room temperature (20-25°C / 68-77°F). Protect from moisture and light. Keep in original container with desiccant when available. Shelf life typically 2-3 years from manufacture date. Keep out of reach of children - overdose risk is high because of the very long half-life.
Not FDA-approved for human use in the United States. Approved for veterinary use in horses (brand name Ventipulmin) and prohibited in food-producing animals under FDA regulation. Approved for human respiratory indications in several European, Latin American, and Asian markets under brands including Spiropent, Broncodil, and Ventipulmin. Classified as a prohibited substance at all times (in and out of competition) by the World Anti-Doping Agency (WADA), USADA, NCAA, and most other sporting bodies.
Put it to work
Open Clenbuterol (Clen) straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Clenbuterol (Clen) in the app →Go deeper
The complete Clenbuterol (Clen) walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗Track it in OnePin. Log vials, draws, and protocols in the app.
Type a name, brand, or tool. Esc closes.